Barclays’s Biohaven BHVN Stock Holding History

Barclays’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-105,600	Closed	-$1.59M	–	5262
2025 Q3	$1.59M	Buy	+105,600	New	+$1.54M	﹤0.01%	3049

Other funds holding BHVN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $173M AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's BHVN Position: Q1 2026 in Review

Barclays reduced its Biohaven (BHVN) stake by 61% in Q1 2026, selling an estimated $2.13M and leaving 125,822 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2720.

Barclays first reported a position in BHVN in Q4 2022 and has held it in 14 quarters since. The position peaked at $14.7M in Q4 2024. 275 funds tracked by Wall St. Rank hold BHVN as of Q1 2026.

Barclays held 125,822 shares of Biohaven worth $1.06M as of Q1 2026.
Barclays sold 195,024 Biohaven shares in Q1 2026, an estimated $2.13M.
Biohaven made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2720 holding.
Barclays first reported a position in Biohaven in Q4 2022 and has held it in 14 quarters since.
Barclays's Biohaven position peaked at $14.7M in Q4 2024.
275 funds tracked by Wall St. Rank held Biohaven as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.